Aurigene Pharmaceutical Services offers systemic LPS challenge induced cytokine release model. The endotoxin LPS (Lipopolysaccharides) constituents of cell wall of gram-negative bacteria when injected into mice/rat will release of various cytokines. We follow this mechanism of action to screen compounds that can modulate any of the various path ways involved in activation of TLR path way to cytokine release (kinase inhibitors, transcription factor inhibitors etc). Depending upon the cytokine of interest ( TNF, IL-1, IL-6 , IL-17 etc ) LPS dose and time point for blood sample collection will be varied. Animals will be grouped based on body weight and test compounds will be administered prior to LPS challenge at a designated time depending upon the pharmacokinetics. Serum /plasma cytokines will be evaluated using ELISA kits and optionally test compounds levels will be determined for PK/PD studies.
Aurigene Pharmaceutical Services is
one of the leading contract research organization (CRO)
provides the best contract research manufacturing
Virtual Tour
Contact Us
Other Services
- ADME DMPK Studies
- Animal Facility
- Carrageenan Induced Paw Edema Model
- GLP and non-GLP Toxicology Studies
- In vitro Genotoxicity Testing
- In vivo Micronucleus Assay
- In vivo Pharmacology Studies & Services | In vivo Efficacy
- LPS Induced Paw Edema Model
- Mammalian Cell Micronucleus Test (in vitro Genotox)
- Murine CT26 colon carcinoma tumor model
- Pharmaceutical Microbiology Testing
- Reverse Passive Cutaneous Arthus Reaction
- Traditional AMES Assay
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.